3-FPM: Difference between revisions

Line 6:

The synthesis and pharmacology of 3-FPM was first reported in a patent filed in 2011.<ref>Blough, B. E., Rothman, R., Landavazo, A., Page, K. M., & Decker, A. M. (2017). U.S. Patent No. 9,617,229. Washington, DC: U.S. Patent and Trademark Office.</ref> Reports of human use first surfaced in early 2015 after it appeared for sale on the online [[research chemical]] market.

[[Subjective effects]] include [[stimulation]], [[focus enhancement|enhanced focus]] and [[motivation enhancement|motivation]], [[thought acceleration]], and [[euphoria]]. Users commonly report that 3-FPM produces classical stimulant effects comparable to those of amphetamine. Many reports describe 3-FPM as having a relatively subtle and controlled stimulant effect which produces less nervousness, insomnia and euphoria than other stimulants, which makes it suitable as a study-aid or productivity-enhancer. A few anecdotal reports indicate some people experience serious ~~immune~~ system reactions~~, often after a large or frequent period of dosing~~.

[[Subjective effects]] include [[stimulation]], [[focus enhancement|enhanced focus]] and [[motivation enhancement|motivation]], [[thought acceleration]], and [[euphoria]]. Users commonly report that 3-FPM produces classical stimulant effects comparable to those of amphetamine. Many reports describe 3-FPM as having a relatively subtle and controlled stimulant effect which produces less nervousness, insomnia and euphoria than other stimulants, which makes it suitable as a study-aid or productivity-enhancer. A few but significant number of anecdotal reports indicate some people experience serious nervous system reactions to 3-FPM<ref>[https://www.reddit.com/r/researchchemicals/comments/l4yvh5/i_had_the_3fpm_that_caused_mild_paralysis_and/]</ref>.

Very little data exists about the pharmacological properties, metabolism, and toxicity of 3-FPM. Due to the lack of information on its properties, it is highly advised to use [[harm reduction practices]] if using this substance.

@@ Line 6: / Line 6: @@
 The synthesis and pharmacology of 3-FPM was first reported in a patent filed in 2011.<ref>Blough, B. E., Rothman, R., Landavazo, A., Page, K. M., & Decker, A. M. (2017). U.S. Patent No. 9,617,229. Washington, DC: U.S. Patent and Trademark Office.</ref> Reports of human use first surfaced in early 2015 after it appeared for sale on the online [[research chemical]] market.
-[[Subjective effects]] include [[stimulation]], [[focus enhancement|enhanced focus]] and [[motivation enhancement|motivation]], [[thought acceleration]], and [[euphoria]]. Users commonly report that 3-FPM produces classical stimulant effects comparable to those of amphetamine. Many reports describe 3-FPM as having a relatively subtle and controlled stimulant effect which produces less nervousness, insomnia and euphoria than other stimulants, which makes it suitable as a study-aid or productivity-enhancer. A few anecdotal reports indicate some people experience serious immune system reactions, often after a large or frequent period of dosing.
+[[Subjective effects]] include [[stimulation]], [[focus enhancement|enhanced focus]] and [[motivation enhancement|motivation]], [[thought acceleration]], and [[euphoria]]. Users commonly report that 3-FPM produces classical stimulant effects comparable to those of amphetamine. Many reports describe 3-FPM as having a relatively subtle and controlled stimulant effect which produces less nervousness, insomnia and euphoria than other stimulants, which makes it suitable as a study-aid or productivity-enhancer. A few but significant number of anecdotal reports indicate some people experience serious nervous system reactions to 3-FPM<ref>[https://www.reddit.com/r/researchchemicals/comments/l4yvh5/i_had_the_3fpm_that_caused_mild_paralysis_and/]</ref>.
 Very little data exists about the pharmacological properties, metabolism, and toxicity of 3-FPM. Due to the lack of information on its properties, it is highly advised to use [[harm reduction practices]] if using this substance.